Optigo Biotherapeutics Announces Presentation at Eyecelerator and
Preclinical Data Poster at the Association for Research in Vision
and Ophthalmology (ARVO) 2025 Annual Meeting
VANCOUVER, Canada — April 24, 2025 — Today, Optigo Biotherapeutics (Optigo), a preclinical-stage biotechnology company focused on discovering and developing transformative therapies for blinding neovascular diseases, announced their presentation of data related to their long-acting retina delivery platform and drug candidates at the Eyecelerator meeting in Park City, Utah on May 2, 2025 and poster acceptance and presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting, taking place in Salt Lake City, Utah on May 6, 2025.
Eyecelerator Presentation Details:
Title: Developing Breakthrough Therapies to Restore Vision
Presenter: Houman Hemmati, MD, PhD, Co-Founder & CMO, Optigo Biotherapeutics
Session Title: Retina - TKI and Drug Delivery Showcase
Presentation Date/Time: Friday, May 2, 2025, 1:59 PM (Mountain)
ARVO Poster Details:
Title: Anchoring of Bispecific Anti-VEGF Molecules to Vitreous Components Extends Half-Life and Duration of Efficacy
Presenter: Christopher Crean, Head Preclinical Development, Optigo Biotherapeutics
Session Title: AMD: New Drugs, Delivery Systems, and Mechanisms of Action
Session Date/Times: Tuesday, May 6, 2025, 3:30–5:15 PM (Mountain)
Purpose: Monthly or bimonthly injections place a significant burden on patients and physicians, underscoring the necessity for longer-acting anti-VEGF formulations to reduce dosing frequency. We engineered novel bi-functional biologics to anchor active molecules to inherent vitreal components and performed a series of rabbit and rat studies to evaluate tolerability, pharmacokinetics (PK), and efficacy in a VEGF challenge model aiming to extend clinical drug delivery intervals to once every 6 to 9 months.
About Optigo Bio:
Optigo Biotherapeutics is a preclinical-stage biotechnology company developing a proprietary platform designed to extend the half-life of biologics by anchoring them to specific proteins in the eye. This approach enables sustained therapeutic presence and improved durability of effect, significantly reducing the frequency of intravitreal injections. Built on this platform, Optigo’s lead asset is a next-generation anti-VEGF therapy targeting the underlying drivers of chronic retinal diseases. By enhancing treatment longevity and addressing limitations of current standard-of-care therapies, Optigo aims to ease the burden on patients and caregivers while delivering meaningful, long-term improvements in vision outcomes. The platform’s modular design also offers potential applicability to other biologics requiring extended half-life.
Media Contact:
RHMM PR
682.553.7283
pr@rhmminc.com